GlassScriptPhysician profile
Jonathan G Vukovich
NPI 1528065539
$3,066.70
in general payments reported to CMS, 2019-2025
27 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $227 · 2021: $206 · 2022: $180 · 2023: $304 · 2024: $1,325 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $586.04 | 2019-2025 | Veozah, Myrbetriq, Xtandi |
| Coloplast Corp | $523.34 | 2024-2025 | |
| Axonics, INC. | $307.04 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $306.37 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $247.60 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $184.43 | 2020-2025 | Axonics, Lumenis Pulse 120h |
| Procept Biorobotics Corporation | $184.21 | 2022-2025 | Aquabeam System |
| Pfizer INC. | $150.28 | 2019-2025 | |
| Endo USA, INC. | $71.41 | 2024-2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $65.34 | 2024 | Endosheath Technology, Urgent PC Neuromodulation System |
| Endo Pharmaceuticals INC. | $60.30 | 2023 | Aveed, Xiaflex |
| Abbvie INC. | $56.64 | 2023-2024 | Botox |
| Antares Pharma, INC. | $37.05 | 2024-2025 | Xyosted |
| Conmed Corporation | $29.75 | 2024 | Airseal |
| Amgen INC. | $28.63 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $27.44 | 2024 | |
| Allergan, INC. | $23.16 | 2019-2021 | |
| Immunitybio, INC. | $22.32 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $21.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.71 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.70 | 2025 | |
| Tolmar, INC. | $18.44 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $16.61 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.95 | 2019 | |
| Rochester Medical Corporation | $15.73 | 2019 | |
| Ambu INC. | $15.33 | 2024 | |
| Myovant Sciences INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Vukovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.